International work sharing for approving new medicines and biosimilar drugs
Official title: Access, new active substance and biosimilar work sharing initiatives
The useful part first
In 20 seconds.
- What changes
- Regulatory agencies now share the review of medicine applications to streamline the approval process.
- Who is affected
- This primarily affects pharmaceutical companies applying for new medicine licences.
- What you may need to do
- No action is stated in the source for the general public.
- When
- In force as an ongoing operational initiative.
- Legal status
- In forceAlready applies
Choose your summary
Key points
The essentials, point by point- 1
The MHRA shares the workload of reviewing new medicine applications with international partners.
- 2
This initiative covers both new active substances and biosimilar medicines.
- 3
Sharing assessments helps ensure timely access to safe and effective treatments.
- 4
Each country still makes its own final decision on whether to approve a medicine.
- 5
The process relies on identical dossiers being submitted to participating regulators.
3 attached files were not read, so details in them are not covered here.
Written automatically by AI from the source text. It can contain mistakes. The impact level is our estimate, not an official rating.
Related publications
More on the same topics, from official sources.
How the government handles your personal information for reciprocal healthcare services.
Reciprocal healthcare privacy notice
Guidance on how to check and understand your fishing vessel licence
Understand your fishing vessel licence
Organisations can receive awards for supporting members of the armed forces community
Defence Employer Recognition Scheme